Who are Placebo to Linagliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anagliptin BID Treatment, alogliptin + pioglitazone, SGLT2i+Metformin+Cofrogliptin, Dapagliflozin/Sitagliptin, MET + Vildagliptin Group, exenatide and sitagliptin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-linagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to Linagliptin — Competitive Intelligence Brief

Placebo to Linagliptin (Placebo to Linagliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Linagliptin (Placebo to Linagliptin) — LG Life Sciences. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Linagliptin TARGET	Placebo to Linagliptin	LG Life Sciences	phase 3	DPP-4 inhibitor	DPP-4
Anagliptin BID Treatment	Anagliptin BID Treatment	JW Pharmaceutical	marketed	DPP-4 inhibitor	Dipeptidyl peptidase-4 (DPP-4)
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ
SGLT2i+Metformin+Cofrogliptin	SGLT2i+Metformin+Cofrogliptin	Huazhong University of Science and Technology	marketed	SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination)	SGLT2, mitochondrial complex I, DPP-4
Dapagliflozin/Sitagliptin	Dapagliflozin/Sitagliptin	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

Merck Sharp & Dohme LLC · 5 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
LG Life Sciences · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ono Pharmaceutical Co. Ltd · 2 drugs in this class
Cinnagen · 1 drug in this class
GRADE Study Group · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Linagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-linagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab